J&J planning submission for Invokana in CKD

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients

Read the full 309 word article

User Sign In